Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Kempower: Q3 numbers were not pretty

Kempower

The Q3 report did not yet show the desired improvement in order intake. The negative impact of high customer stock levels on demand looks set to continue until early 2025. We still expect growth to turn positive in 2025, but there is considerable uncertainty. Analyst Pauli Lohi summarizes.  

Content:
00:00 Intro
00:08 Company’s situation
01:28 Q3 
02:00 Inventory levels 
03:11 Market situation
04:25 Most important thing in Kempower’s case 
05:29 Valuation and recommendation 

Stay up to date
Analyst Interviews

Recent videos

AKTIER MED FRIIS - UGE 2 2026
09.01.2026, 12.00
HCA Morgenbørs 09/01 - Futures peger op i Europa og fokus på afgørelse om Trumps tariffer
09.01.2026, 09.28 Gubra
Herantis Pharma Plc, Phase 1b biomarker data webcast
08.01.2026, 11.00 Herantis Pharma
HCA Morgenbørs 08/01 - Røde futures og fokus på kursmålsjusteringer
08.01.2026, 09.18 Novo Nordisk
HCA Morgenbørs 07/01 - Vi ser ind i en blandet udvikling på de globale futures-markeder med Europa i plus og USA i minus
07.01.2026, 09.58 RTX
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.